Pfizer (PFE)
Market Price (11/13/2025): $25.82 | Market Cap: $146.8 BilSector: Health Care | Industry: Pharmaceuticals
Pfizer (PFE)
Market Price (11/13/2025): $25.82Market Cap: $146.8 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 13%, Dividend Yield is 6.6%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 9.1%, FCF Yield is 7.1% | Trading close to highsDist 52W High is -3.8% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -13%, Rev Chg QQuarterly Revenue Change % is -5.9% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 25% | Weak multi-year price returns2Y Excs Rtn is -60%, 3Y Excs Rtn is -115% | |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17%, CFO LTM is 13 Bil, FCF LTM is 10 Bil | ||
| Low stock price volatilityVol 12M is 27% | ||
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include mRNA Technology, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 13%, Dividend Yield is 6.6%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 9.1%, FCF Yield is 7.1% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 25% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17%, CFO LTM is 13 Bil, FCF LTM is 10 Bil |
| Low stock price volatilityVol 12M is 27% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include mRNA Technology, Show more. |
| Trading close to highsDist 52W High is -3.8% |
| Weak multi-year price returns2Y Excs Rtn is -60%, 3Y Excs Rtn is -115% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -13%, Rev Chg QQuarterly Revenue Change % is -5.9% |
Market Valuation & Key Metrics
PFE Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Pfizer (PFE) experienced significant events between July 31, 2025, and November 13, 2025, that influenced its stock performance. While the precise 13% movement cannot be fully confirmed without specific stock data for July 31, 2025, the following key points highlight the major developments that would have driven stock fluctuations during this period:
1. Q3 2025 Earnings Report: On November 4, 2025, Pfizer announced adjusted diluted earnings per share (EPS) of $0.87 for the third quarter of 2025, which significantly surpassed analyst expectations of $0.66. However, the company's revenue of $16.7 billion slightly missed the forecast of $16.8 billion, representing a 7% operational decrease year-over-year due to a notable decline in COVID-19 product sales, with Paxlovid sales dropping 55% and Comirnaty sales down 20% operationally. Despite the EPS beat, the stock initially dipped, reflecting investor concerns over the revenue decline.
2. Acquisition of Metsera: Pfizer finalized its acquisition of Metsera, an obesity biotech, for up to $10 billion by November 10, 2025. This came after a competitive bidding war with Novo Nordisk. Pfizer's initial offer was for up to $7.3 billion in September 2025, but it was increased to secure the deal. Metsera's board ultimately favored Pfizer's offer, citing lower legal and regulatory risks, particularly following scrutiny from the U.S. Federal Trade Commission regarding Novo Nordisk's bid. This acquisition is viewed as a strategic move to drive long-term growth in the cardiometabolic market.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PFE Return | -2% | 67% | -10% | -41% | -2% | 5% | -12% |
| Peers Return | 9% | 21% | 17% | 5% | 9% | 18% | 107% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| PFE Win Rate | 33% | 75% | 42% | 17% | 33% | 40% | |
| Peers Win Rate | 52% | 55% | 60% | 45% | 48% | 58% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| PFE Max Drawdown | -27% | -8% | -27% | -47% | -11% | -17% | |
| Peers Max Drawdown | -20% | -7% | -10% | -17% | -10% | -13% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: RHHBY, LLY, JNJ, MRK, BMY. See PFE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 11/12/2025 (YTD)
How Low Can It Go
| Event | PFE | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -57.3% | -25.4% |
| % Gain to Breakeven | 134.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -30.0% | -33.9% |
| % Gain to Breakeven | 42.9% | 51.3% |
| Time to Breakeven | 254 days | 148 days |
| 2018 Correction | ||
| % Loss | -25.9% | -19.8% |
| % Gain to Breakeven | 35.0% | 24.7% |
| Time to Breakeven | 727 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -57.9% | -56.8% |
| % Gain to Breakeven | 137.4% | 131.3% |
| Time to Breakeven | 1429 days | 1480 days |
Compare to RHHBY, LLY, JNJ, MRK, BMY
In The Past
Pfizer's stock fell -57.3% during the 2022 Inflation Shock from a high on 12/16/2021. A -57.3% loss requires a 134.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | Date | |
|---|---|---|---|
| DASHBOARDS | |||
| Pfizer Earnings Notes | |||
| 3 Forces That Could Shake Pfizer Stock | |||
| Should You Buy Pfizer Stock? | Buy or Fear | ||
| What Could Send Pfizer Stock Soaring | |||
| Ten-Year Tally: PFE Returns $50 Bil to Shareholders | |||
| Is Pfizer Stock Built to Withstand a Pullback? | Return | ||
| Day 9 of Loss Streak for Pfizer Stock with -11% Return (vs. -3.8% YTD) [10/16/2025] | Notification | ||
| Day 8 of Loss Streak for Pfizer Stock with -11% Return (vs. -3.1% YTD) [10/15/2025] | Notification | ||
| Day 7 of Loss Streak for Pfizer Stock with -10% Return (vs. -2.6% YTD) [10/14/2025] | Notification | ||
| Day 6 of Loss Streak for Pfizer Stock with -9.6% Return (vs. -1.8% YTD) [10/13/2025] | Notification | ||
| ARTICLES | |||
| How Does Pfizer Stock Stack Up Against Its Peers? | November 7th, 2025 | ||
| Pfizer Stock To $32? | November 4th, 2025 | ||
| What Could Send Pfizer Stock Soaring | October 31st, 2025 | ||
| Pfizer Stock Pays Out $50 Bil to Investors in 10 Years | October 14th, 2025 | ||
| PFE Surges 6.8% In A Single Day, Time To Buy The Stock? | October 2nd, 2025 |
Trade Ideas
Select past ideas related to PFE. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 10312025 | GDRX | GoodRx | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -9.2% | -9.2% | -10.1% |
| 10312025 | DXCM | DexCom | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 2.4% | 2.4% | -5.8% |
| 10242025 | ACHC | Acadia Healthcare | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -25.6% | -25.6% | -25.6% |
| 10102025 | PBH | Prestige Consumer Healthcare | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -0.8% | -0.8% | -1.9% |
| 10032025 | REGN | Regeneron Pharmaceuticals | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 13.6% | 13.6% | -7.0% |
| 05312025 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 14.0% | 14.0% | -1.6% |
| 02282023 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -8.9% | -29.9% | -33.3% |
| 08312022 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -9.6% | -18.6% | -19.5% |
| 02282022 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.1% | -10.6% | -10.6% |
| 03312020 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 13.0% | 15.6% | -2.7% |
| 09302019 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -7.3% | 4.7% | -19.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 10312025 | GDRX | GoodRx | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -9.2% | -9.2% | -10.1% |
| 10312025 | DXCM | DexCom | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 2.4% | 2.4% | -5.8% |
| 10242025 | ACHC | Acadia Healthcare | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -25.6% | -25.6% | -25.6% |
| 10102025 | PBH | Prestige Consumer Healthcare | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -0.8% | -0.8% | -1.9% |
| 10032025 | REGN | Regeneron Pharmaceuticals | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 13.6% | 13.6% | -7.0% |
| 05312025 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 14.0% | 14.0% | -1.6% |
| 02282023 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -8.9% | -29.9% | -33.3% |
| 08312022 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -9.6% | -18.6% | -19.5% |
| 02282022 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.1% | -10.6% | -10.6% |
| 03312020 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 13.0% | 15.6% | -2.7% |
| 09302019 | PFE | Pfizer | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -7.3% | 4.7% | -19.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Pfizer
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 70.27 |
| Mkt Cap | 228.2 |
| Rev LTM | 62,786 |
| Op Inc LTM | 22,391 |
| FCF LTM | 13,049 |
| FCF 3Y Avg | 13,598 |
| CFO LTM | 16,621 |
| CFO 3Y Avg | 14,846 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.9% |
| Rev Chg 3Y Avg | 2.9% |
| Rev Chg Q | 3.7% |
| QoQ Delta Rev Chg LTM | 1.0% |
| Op Mgn LTM | 26.2% |
| Op Mgn 3Y Avg | 23.7% |
| QoQ Delta Op Mgn LTM | 1.8% |
| CFO/Rev LTM | 26.3% |
| CFO/Rev 3Y Avg | 26.4% |
| FCF/Rev LTM | 20.3% |
| FCF/Rev 3Y Avg | 20.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 228.2 |
| P/S | 3.6 |
| P/EBIT | 12.4 |
| P/E | 16.5 |
| P/CFO | 13.4 |
| Total Yield | 11.0% |
| Dividend Yield | 3.6% |
| FCF Yield 3Y Avg | 5.5% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.6% |
| 3M Rtn | 12.0% |
| 6M Rtn | 24.3% |
| 12M Rtn | 15.6% |
| 3Y Rtn | 12.1% |
| 1M Excs Rtn | 4.6% |
| 3M Excs Rtn | 5.9% |
| 6M Excs Rtn | 8.0% |
| 12M Excs Rtn | -0.7% |
| 3Y Excs Rtn | -68.4% |
Comparison Analyses
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Biopharma | 58,237 | 98,988 | 79,557 | 40,724 | |
| Other business activities | 1,316 | 1,342 | 1,731 | 926 | |
| Consumer Healthcare Business | 2,082 | ||||
| Hospital | 7,772 | ||||
| Inflammation & Immunology (I&I) | 4,733 | ||||
| Internal Medicine | 8,790 | ||||
| Oncology | 9,014 | ||||
| Rare Disease | 2,278 | ||||
| Vaccines | 6,504 | ||||
| Total | 59,553 | 100,330 | 81,288 | 41,650 | 41,173 |
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/4/2025 | -1.5% | ||
| 8/5/2025 | 5.2% | 4.5% | 5.4% |
| 4/29/2025 | 3.2% | 3.6% | 2.5% |
| 2/4/2025 | -1.3% | -1.3% | -1.0% |
| 10/29/2024 | -1.4% | -3.8% | -9.3% |
| 7/30/2024 | 2.2% | -3.2% | -6.2% |
| 5/1/2024 | 6.1% | 8.4% | 11.7% |
| 1/30/2024 | -1.7% | -3.3% | -1.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 10 | 9 |
| # Negative | 12 | 14 | 15 |
| Median Positive | 3.2% | 3.4% | 8.6% |
| Median Negative | -1.4% | -3.3% | -5.1% |
| Max Positive | 6.1% | 11.7% | 26.4% |
| Max Negative | -5.0% | -6.4% | -12.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11042025 | 10-Q 9/28/2025 |
| 6302025 | 8052025 | 10-Q 6/29/2025 |
| 3312025 | 5052025 | 10-Q 3/30/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 11042024 | 10-Q 9/29/2024 |
| 6302024 | 8052024 | 10-Q 6/30/2024 |
| 3312024 | 5082024 | 10-Q 3/31/2024 |
| 12312023 | 2222024 | 10-K 12/31/2023 |
| 9302023 | 11082023 | 10-Q 10/1/2023 |
| 6302023 | 8092023 | 10-Q 7/2/2023 |
| 3312023 | 5102023 | 10-Q 4/2/2023 |
| 12312022 | 2232023 | 10-K 12/31/2022 |
| 9302022 | 11092022 | 10-Q 10/2/2022 |
| 6302022 | 8102022 | 10-Q 7/3/2022 |
| 3312022 | 5112022 | 10-Q 4/3/2022 |
| 12312021 | 2242022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |